HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AB&B BIO-TECH-B

41.100

+0.5001.23%

Volume:118.40K

Turnover:4.88M

Market Cap:16.17B

PE:-52.23

High:42.000

Open:40.600

Low:40.200

Close:40.600

52wk High:59.600

52wk Low:33.000

Shares:393.44M

HK Float Shares:296.36M

Volume Ratio:1.98

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.787

ROE:--

ROA:--

PB:438.74

PE(LYR):-52.23

PS:45.61

Loading ...

Overview Company News Filings

Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines

Bulletin Express

AB&B BIO-TECH-B (02627) Initiates Phase I Clinical Trials for Quadrivalent and Trivalent Influenza Subunit Vaccines (Adjuvanted)

AB&B Bio-Tech Launches Phase I Trial for Adjuvanted Influenza Vaccines

AB&B BIO-TECH-B (02627) Leads the Way in Influenza Vaccines, Poised to Address Unmet Needs in Maternal and Infant Immunization

Ab&B Bio-Tech CO., LTD. JS (02627) Publishes Monthly Return with Unchanged Share Capital

Bulletin Express

AB&B BIO-TECH-B (02627) Accelerates Commercialization as Expanded-Age Flu Vaccine Completes First Doses Nationwide

Ab&B Bio-Tech Applies for Hong Kong-Listed Share Full Circulation

MT Newswires Live

AB&B BIO-TECH-B (02627) Applies for Full Circulation of H Shares

Hong Kong Stock Alert | AB&B BIO-TECH-B (02627) Surges Over 8% as Quadrivalent Influenza Virus Subunit Vaccine Enters Commercial Insurance Preliminary Review List with Significant Market Scarcity

Hong Kong Stock Market Preview | Fed Beige Book Shows Employment Levels Generally Stable, September Rate Cut Probability at 96.6%

Ab&B Bio-Tech's Influenza Vaccine Application Gets China Nod

MT Newswires Live

AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine

AB&B BIO-TECH-B (02627): Marketing Application for Quadrivalent Influenza Virus Subunit Vaccine Approved by National Medical Products Administration

Ab&B Bio Tech Co Ltd Js - Approval of Application for Quadrivalent Subunit Influenza Vaccine by China's Nmpa

THOMSON REUTERS

Interim Report Shows Revenue Surge of Over 900% YoY: Examining the "Investment Certainty" Behind AB&B BIO-TECH-B's (02627) Core Innovation Technology

Hong Kong Stock Movement | AB&B BIO-TECH-B (02627) Closes Up 1.35% with Interim Revenue Surging Over 9 Times Year-on-Year

AB&B BIO-TECH-B (02627) Reports Interim Results with Revenue of RMB 71.12 Million, Surging 919.25% Year-on-Year

AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)

Ab&B Bio Tech Co Ltd Js - Hy Loss RMB121.5 Mln

THOMSON REUTERS

Hong Kong Stock Alert | AB&B BIO-TECH-B (02627) Surges Over 7% as Recombinant RSV Vaccine Receives IND Approval in Both China and US

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02627/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02627","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","market":"HK","secType":"STK","nameCN":"AB&B BIO-TECH-B","latestPrice":41.1,"timestamp":1763091095642,"preClose":40.6,"halted":0,"volume":118400,"delay":0,"floatShares":296361845,"shares":393442600,"eps":-0.7869544990172238,"marketStatus":"Trading","change":0.5,"latestTime":"11-14 11:33:03","open":40.6,"high":42,"low":40.2,"amount":4883312,"amplitude":0.044335,"askPrice":41.24,"askSize":200,"bidPrice":41.1,"bidSize":800,"shortable":0,"etf":0,"ttmEps":-0.68265541925309,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1763092800000},"marketStatusCode":2,"adr":0,"listingDate":1754841600000,"exchange":"SEHK","adjPreClose":40.6,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":1.981741,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","floatShares":296361845,"roa":"--","roe":"--","lyrEps":-0.786954,"volumeRatio":1.981741,"shares":393442600,"dividePrice":0,"high":42,"amplitude":0.044335,"preClose":40.6,"low":40.2,"week52Low":33,"pbRate":"438.74","psRate":"45.61","week52High":59.6,"institutionHeld":0,"latestPrice":41.1,"committee":0.6,"eps":-0.7869544990172238,"divideRate":0,"volume":118400,"delay":0,"ttmEps":-0.68265541925309,"open":40.6,"prevYearClose":12.9,"prevWeekClose":40.5,"prevMonthClose":40.3,"prevQuarterClose":49.3,"fiveDayClose":40.5,"twentyDayClose":45.38,"sixtyDayClose":51.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02627\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02627\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02627\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02627\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02627","date":"2025-11-13","current":-59.495231,"percent":0.621212,"low":-83.59026,"twenty":-76.940683,"median":-66.554289,"eighty":-63.514146,"high":-18.07815,"avg":-68.00407,"sd":9.790665,"marketCap":15973769560},"quantilePoints":[{"date":"2025-08-08","current":-18.07815,"twenty":-18.07815,"median":-18.07815,"eighty":-18.07815,"marketCap":5586884920},{"date":"2025-08-15","current":-60.155426,"twenty":-60.155426,"median":-56.438909,"eighty":-42.414982,"marketCap":18562621868},{"date":"2025-08-22","current":-65.870069,"twenty":-65.897052,"median":-63.746879,"eighty":-55.654938,"marketCap":20262293900},{"date":"2025-08-29","current":-64.920623,"twenty":-66.830053,"median":-65.395346,"eighty":-57.22288,"marketCap":20065572600},{"date":"2025-09-05","current":-62.716917,"twenty":-66.416243,"median":-63.912829,"eighty":-60.155426,"marketCap":19365244772},{"date":"2025-09-12","current":-62.655098,"twenty":-66.251138,"median":-63.08644,"eighty":-59.27469,"marketCap":19380982476},{"date":"2025-09-19","current":-81.048551,"twenty":-68.315951,"median":-63.912829,"eighty":-59.882299,"marketCap":19888523430},{"date":"2025-09-26","current":-77.095946,"twenty":-77.153546,"median":-65.395346,"eighty":-60.155426,"marketCap":18869507096},{"date":"2025-10-03","current":-76.784092,"twenty":-77.86406,"median":-66.074095,"eighty":-61.128611,"marketCap":18838031688},{"date":"2025-10-10","current":-75.450727,"twenty":-78.338288,"median":-66.623148,"eighty":-61.710077,"marketCap":18483933348},{"date":"2025-10-17","current":-70.044793,"twenty":-77.841467,"median":-68.315951,"eighty":-62.332762,"marketCap":17146228508},{"date":"2025-10-24","current":-70.694139,"twenty":-77.356453,"median":-69.86748,"eighty":-62.632094,"marketCap":17311474400},{"date":"2025-10-31","current":-64.652972,"twenty":-77.130506,"median":-68.586563,"eighty":-62.679826,"marketCap":15855736780},{"date":"2025-11-07","current":-65.014442,"twenty":-77.0495,"median":-67.012733,"eighty":-63.012535,"marketCap":15934425300},{"date":"2025-11-13","current":-64.99081,"twenty":-76.940683,"median":-66.554289,"eighty":-63.514146,"marketCap":15973769560}],"updateTime":1763079530237},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02627\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1178407621","title":"Ab&B Bio-Tech (2627) Announces Commencement of Phase I Clinical Trials for Influenza Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=1178407621","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178407621?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:42","pubTimestamp":1763023341,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS (2627) has initiated Phase I clinical trials of its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. According to the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"1119410585","title":"AB&B BIO-TECH-B (02627) Initiates Phase I Clinical Trials for Quadrivalent and Trivalent Influenza Subunit Vaccines (Adjuvanted)","url":"https://stock-news.laohu8.com/highlight/detail?id=1119410585","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119410585?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:42","pubTimestamp":1763023335,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced the initiation of Phase I clinical trials for its quadrivalent influenza virus subunit vaccine (adjuvanted) and trivalent influenza virus subunit vaccine...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627","159646"],"gpt_icon":0},{"id":"2583554708","title":"AB&B Bio-Tech Launches Phase I Trial for Adjuvanted Influenza Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583554708?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:33","pubTimestamp":1763022798,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co. Ltd. JS has announced the commencement of Phase I clinical trials for its adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. The company recently received Investigational New Drug approvals from the National Medical Products Administration of the People's Republic of China for these vaccine candidates. No results from these clinical trials have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLQ1Rjz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1109814019","title":"AB&B BIO-TECH-B (02627) Leads the Way in Influenza Vaccines, Poised to Address Unmet Needs in Maternal and Infant Immunization","url":"https://stock-news.laohu8.com/highlight/detail?id=1109814019","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109814019?lang=en_us&edition=fundamental","pubTime":"2025-11-06 12:02","pubTimestamp":1762401771,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) has recently achieved significant milestones. The company’s flagship product—China’s only quadrivalent influenza subunit vaccine covering all age groups—has once again been...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","159646","BK1161"],"gpt_icon":0},{"id":"1139079217","title":"Ab&B Bio-Tech CO., LTD. JS (02627) Publishes Monthly Return with Unchanged Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1139079217","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139079217?lang=en_us&edition=fundamental","pubTime":"2025-11-04 16:45","pubTimestamp":1762245959,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS (02627) submitted its Monthly Return for the period ended 31 October 2025 on 4 November 2025. According to the announcement, the company’s authorized and registered share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"1169114575","title":"AB&B BIO-TECH-B (02627) Accelerates Commercialization as Expanded-Age Flu Vaccine Completes First Doses Nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=1169114575","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169114575?lang=en_us&edition=fundamental","pubTime":"2025-11-03 12:56","pubTimestamp":1762145787,"startTime":"0","endTime":"0","summary":"This autumn and winter, the Asia-Pacific region is experiencing an earlier and more severe flu season than usual. In Japan, the flu season arrived five weeks earlier than last year, with over 9,000...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"2575804977","title":"Ab&B Bio-Tech Applies for Hong Kong-Listed Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2575804977","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575804977?lang=en_us&edition=fundamental","pubTime":"2025-10-15 21:17","pubTimestamp":1760534240,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech (HKG:2627) applied to the CSRC for the conversion of 81.7 million unlisted shares into Hong Kong-listed shares, a Wednesday Hong Kong bourse filing said.The biotech firm said it is yet to complete the filing of the application and will make further announcements as and when needed.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1120179228","title":"AB&B BIO-TECH-B (02627) Applies for Full Circulation of H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1120179228","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120179228?lang=en_us&edition=fundamental","pubTime":"2025-10-15 19:20","pubTimestamp":1760527214,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that on October 15, 2025, the company submitted an application to the China Securities Regulatory Commission to convert 81.662 million unlisted shares into H shares and to list these shares on the Hong Kong Stock Exchange.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1190728184","title":"Hong Kong Stock Alert | AB&B BIO-TECH-B (02627) Surges Over 8% as Quadrivalent Influenza Virus Subunit Vaccine Enters Commercial Insurance Preliminary Review List with Significant Market Scarcity","url":"https://stock-news.laohu8.com/highlight/detail?id=1190728184","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190728184?lang=en_us&edition=fundamental","pubTime":"2025-09-16 11:44","pubTimestamp":1757994262,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) surged over 8%. As of press time, the stock was up 7.49% to HK$51.25 with a turnover of HK$18.463 million. On the news front, AB&B BIO-TECH-B recently announced that the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","02627","BK4614","HSCEI","07226","159646","BK1161"],"gpt_icon":1},{"id":"1142605337","title":"Hong Kong Stock Market Preview | Fed Beige Book Shows Employment Levels Generally Stable, September Rate Cut Probability at 96.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142605337","media":"Stock News","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142605337?lang=en_us&edition=fundamental","pubTime":"2025-09-04 07:43","pubTimestamp":1756942981,"startTime":"0","endTime":"0","summary":"**Today's Headlines** Fed Beige Book Shows Employment Levels Generally Stable, September Rate Cut Probability at 96.6% The Federal Reserve's Beige Book indicated that eleven districts reported...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","HSCEI","BK1613","SSO","BK1119","YANG","07226","UPRO","BK1183","SH","OEF","BK4550","OEX","00315","HSTECH","BK4534","02627","BK1536","SDS",".SPX","BK4581","BK4585","ESmain","BK1161","BK1152","SPY","SPXU","BK4504","BK4614","IVV","09863","BK4588","09880","MESmain"],"gpt_icon":1},{"id":"2564398090","title":"Ab&B Bio-Tech's Influenza Vaccine Application Gets China Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398090","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398090?lang=en_us&edition=fundamental","pubTime":"2025-09-03 19:43","pubTimestamp":1756899811,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech's (HKG:2627) new drug application for the quadrivalent subunit influenza vaccine for individuals aged six to 35 months was approved by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2564643483","title":"AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2564643483","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564643483?lang=en_us&edition=fundamental","pubTime":"2025-09-03 17:59","pubTimestamp":1756893552,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co. Ltd. JS has received regulatory approval from the National Medical Products Administration  of the People's Republic of China for its new quadrivalent subunit influenza vaccine. This vaccine, designed for individuals aged 6 to 35 months, represents the first and only quadrivalent subunit influenza vaccine approved in China for all age groups at full dosage level. The product offers comprehensive protection, high antigen purity, and low risks of adverse reactions. The company, focused on innovative vaccine development, aims to replace traditional and imported vaccines in China and expand into international markets. Shareholders and potential investors are advised to exercise caution when dealing with the company's securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL8mynwc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1101919233","title":"AB&B BIO-TECH-B (02627): Marketing Application for Quadrivalent Influenza Virus Subunit Vaccine Approved by National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=1101919233","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101919233?lang=en_us&edition=fundamental","pubTime":"2025-09-03 17:40","pubTimestamp":1756892433,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that the company's board of directors is pleased to announce that China's National Medical Products Administration (NMPA) has approved the group's new drug...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627","159646"],"gpt_icon":0},{"id":"2564855361","title":"Ab&B Bio Tech Co Ltd Js - Approval of Application for Quadrivalent Subunit Influenza Vaccine by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2564855361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564855361?lang=en_us&edition=fundamental","pubTime":"2025-09-03 17:34","pubTimestamp":1756892069,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UQ01A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1104271548","title":"Interim Report Shows Revenue Surge of Over 900% YoY: Examining the \"Investment Certainty\" Behind AB&B BIO-TECH-B's (02627) Core Innovation Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1104271548","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104271548?lang=en_us&edition=fundamental","pubTime":"2025-08-28 20:14","pubTimestamp":1756383248,"startTime":"0","endTime":"0","summary":"According to Goldman Sachs' latest macro assessment released in August, market expectations for a Federal Reserve rate cut in September are heating up, potentially attracting more global capital into...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1159501544","title":"Hong Kong Stock Movement | AB&B BIO-TECH-B (02627) Closes Up 1.35% with Interim Revenue Surging Over 9 Times Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1159501544","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159501544?lang=en_us&edition=fundamental","pubTime":"2025-08-28 19:00","pubTimestamp":1756378858,"startTime":"0","endTime":"0","summary":"On August 28, AB&B BIO-TECH-B (02627) showed active performance in late trading with its stock price surging rapidly. The stock closed up 1.35% at HK$52.5. After market close on the same day, AB&B...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1133141248","title":"AB&B BIO-TECH-B (02627) Reports Interim Results with Revenue of RMB 71.12 Million, Surging 919.25% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1133141248","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133141248?lang=en_us&edition=fundamental","pubTime":"2025-08-28 16:52","pubTimestamp":1756371144,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced its interim results for the six months ended June 30, 2025, reporting group revenue of RMB 71.123 million, representing a substantial increase of 919.25%...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"2562708950","title":"AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)","url":"https://stock-news.laohu8.com/highlight/detail?id=2562708950","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562708950?lang=en_us&edition=fundamental","pubTime":"2025-08-28 16:35","pubTimestamp":1756370147,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB . Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL6YSTmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"2562089814","title":"Ab&B Bio Tech Co Ltd Js -  Hy Loss RMB121.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562089814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562089814?lang=en_us&edition=fundamental","pubTime":"2025-08-28 16:32","pubTimestamp":1756369971,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UJ17N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1163377062","title":"Hong Kong Stock Alert | AB&B BIO-TECH-B (02627) Surges Over 7% as Recombinant RSV Vaccine Receives IND Approval in Both China and US","url":"https://stock-news.laohu8.com/highlight/detail?id=1163377062","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163377062?lang=en_us&edition=fundamental","pubTime":"2025-08-18 09:48","pubTimestamp":1755481694,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) surged over 7%. As of press time, the stock climbed 7.25% to HK$50.6, with a turnover of HK$136.446 million. On the news front, AB&B BIO-TECH-B announced that the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159646","02627"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}